Cargando…

Prognostic scores in primary biliary cholangitis patients with advanced disease

BACKGROUND: Due to the chronic progressive disease characteristics of primary biliary cholangitis (PBC), patients with advanced PBC should not be ignored. Most prognostic score studies have focused on early stage PBC. AIM: To compare the prognostic value of various risk scores in advanced PBC to hel...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Juan, Xu, Jia-Min, Fu, Hai-Yan, Xie, Nan, Bao, Wei-Min, Tang, Ying-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494590/
https://www.ncbi.nlm.nih.gov/pubmed/37701680
http://dx.doi.org/10.4240/wjgs.v15.i8.1774
_version_ 1785104725658566656
author Feng, Juan
Xu, Jia-Min
Fu, Hai-Yan
Xie, Nan
Bao, Wei-Min
Tang, Ying-Mei
author_facet Feng, Juan
Xu, Jia-Min
Fu, Hai-Yan
Xie, Nan
Bao, Wei-Min
Tang, Ying-Mei
author_sort Feng, Juan
collection PubMed
description BACKGROUND: Due to the chronic progressive disease characteristics of primary biliary cholangitis (PBC), patients with advanced PBC should not be ignored. Most prognostic score studies have focused on early stage PBC. AIM: To compare the prognostic value of various risk scores in advanced PBC to help PBC patients obtain more monitoring and assessment. METHODS: This study considered patients diagnosed with PBC during hospitalization between 2015 and 2021. The clinical stage was primarily middle and late, and patients usually took ursodeoxycholic acid (UDCA) after diagnosis. The discriminatory performance of the scores was assessed with concordance statistics at baseline and after 1 year of UDCA treatment. Telephone follow-up was conducted to analyze the course and disease-associated outcomes. The follow-up deadline was December 31, 2021. We compared the risk score indexes between those patients who reached a composite end point of death or liver transplantation (LT) and those who remained alive at the deadline. The combined performance of prognostic scores in estimating the risk of death or LT after 1 year of UDCA treatment was assessed using Cox regression analyses. Predictive accuracy was evaluated by comparing predicted and actual survival through Kaplan-Meier analyses. RESULTS: We included 397 patients who were first diagnosed with PBC during hospitalization and received UDCA treatment; most disease stages were advanced. After an average of 6.4 ± 1.4 years of follow-up, 82 patients had died, and 4 patients had undergone LT. After receiving UDCA treatment for 1 year, the score with the best discrimination performance was the Mayo, with a concordance statistic of 0.740 (95% confidence interval: 0.690-0.791). The albumin-bilirubin, GLOBE, and Mayo scores tended to overestimate transplant-free survival. Comparing 7 years of calibration results showed that the Mayo score was the best model. CONCLUSION: The Mayo, GLOBE, UK-PBC, and ALBI scores demonstrated comparable discriminating performance for advanced stage PBC. The Mayo score showed optimal discriminatory performance and excellent predictive accuracy.
format Online
Article
Text
id pubmed-10494590
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-104945902023-09-12 Prognostic scores in primary biliary cholangitis patients with advanced disease Feng, Juan Xu, Jia-Min Fu, Hai-Yan Xie, Nan Bao, Wei-Min Tang, Ying-Mei World J Gastrointest Surg Observational Study BACKGROUND: Due to the chronic progressive disease characteristics of primary biliary cholangitis (PBC), patients with advanced PBC should not be ignored. Most prognostic score studies have focused on early stage PBC. AIM: To compare the prognostic value of various risk scores in advanced PBC to help PBC patients obtain more monitoring and assessment. METHODS: This study considered patients diagnosed with PBC during hospitalization between 2015 and 2021. The clinical stage was primarily middle and late, and patients usually took ursodeoxycholic acid (UDCA) after diagnosis. The discriminatory performance of the scores was assessed with concordance statistics at baseline and after 1 year of UDCA treatment. Telephone follow-up was conducted to analyze the course and disease-associated outcomes. The follow-up deadline was December 31, 2021. We compared the risk score indexes between those patients who reached a composite end point of death or liver transplantation (LT) and those who remained alive at the deadline. The combined performance of prognostic scores in estimating the risk of death or LT after 1 year of UDCA treatment was assessed using Cox regression analyses. Predictive accuracy was evaluated by comparing predicted and actual survival through Kaplan-Meier analyses. RESULTS: We included 397 patients who were first diagnosed with PBC during hospitalization and received UDCA treatment; most disease stages were advanced. After an average of 6.4 ± 1.4 years of follow-up, 82 patients had died, and 4 patients had undergone LT. After receiving UDCA treatment for 1 year, the score with the best discrimination performance was the Mayo, with a concordance statistic of 0.740 (95% confidence interval: 0.690-0.791). The albumin-bilirubin, GLOBE, and Mayo scores tended to overestimate transplant-free survival. Comparing 7 years of calibration results showed that the Mayo score was the best model. CONCLUSION: The Mayo, GLOBE, UK-PBC, and ALBI scores demonstrated comparable discriminating performance for advanced stage PBC. The Mayo score showed optimal discriminatory performance and excellent predictive accuracy. Baishideng Publishing Group Inc 2023-08-27 2023-08-27 /pmc/articles/PMC10494590/ /pubmed/37701680 http://dx.doi.org/10.4240/wjgs.v15.i8.1774 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Observational Study
Feng, Juan
Xu, Jia-Min
Fu, Hai-Yan
Xie, Nan
Bao, Wei-Min
Tang, Ying-Mei
Prognostic scores in primary biliary cholangitis patients with advanced disease
title Prognostic scores in primary biliary cholangitis patients with advanced disease
title_full Prognostic scores in primary biliary cholangitis patients with advanced disease
title_fullStr Prognostic scores in primary biliary cholangitis patients with advanced disease
title_full_unstemmed Prognostic scores in primary biliary cholangitis patients with advanced disease
title_short Prognostic scores in primary biliary cholangitis patients with advanced disease
title_sort prognostic scores in primary biliary cholangitis patients with advanced disease
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494590/
https://www.ncbi.nlm.nih.gov/pubmed/37701680
http://dx.doi.org/10.4240/wjgs.v15.i8.1774
work_keys_str_mv AT fengjuan prognosticscoresinprimarybiliarycholangitispatientswithadvanceddisease
AT xujiamin prognosticscoresinprimarybiliarycholangitispatientswithadvanceddisease
AT fuhaiyan prognosticscoresinprimarybiliarycholangitispatientswithadvanceddisease
AT xienan prognosticscoresinprimarybiliarycholangitispatientswithadvanceddisease
AT baoweimin prognosticscoresinprimarybiliarycholangitispatientswithadvanceddisease
AT tangyingmei prognosticscoresinprimarybiliarycholangitispatientswithadvanceddisease